AAAAAA

   
Results: 1-8 |
Results: 8
Treatment of proximal deep vein thrombosis with a novel synthetic compound(SR90107A/ORG31540) with pure anti-factor Xa activity - A phase II evaluation
Authors: Buller, HR Cariou, R Gallus, A Gent, M Ginsberg, J Prins, MH Lensing, A Levi, M Nurmohammed, N Hirsh, J Roberts, R ten Cate, JW Decousus, H Mismetti, P Buchmuller, A Charlet, V Viallon, A van der Meer, J Meinardi, JR Meijer, K Piovella, F Barone, M Beltrametti, C Serafini, S Kraaijenhagen, RA Koopman, MMW Jagt, HHT Muller, MBR Kooy, MV Nauta, S Gallus, AS Coghlan, D Rich, C Prandoni, P Scudeller, A Scarano, L Girolami, A Baker, R Tan, E Cooney, J Eikelboom, J Ninet, J Dolmazon, C Madoux, MHG Coppere, B Nenci, GG Agnelli, G Falcinelli, F Morini, M d'Angelo, A Crippa, L d'Angelo, SV Chong, B Chestreman, C Malvin, J Eisbacher, M MacGillavry, MR Brandjes, DPM Beaumont, JFM Olmos, RAV Turpie, AGG Johnson, J Nowacki, B Anderson, D Pleasance, S Mitchell, M Ockelford, P Bennett, A Jones, R Porteous, F Weitz, J Kearon, C Simonneau, G Parent, F Douketis, J Schnurr, T Hainaut, P Petit, B Jaumotte, C Huisman, MV van Poelgeest, MIE Meinders, AE van Oostayen, JA Beer, J Lugli, A Pederiva, S Ginsberg, J Brill-Edwards, P Stevens, P Bassand, JP Seronde, MF Kassis, J Fortin, M Faivre, R Petiteau, PY Verhaeghe, R Wells, P Lewandowski, B Touchie, D Banga, JD Hartmann, IJC Zeguers, VJM Desjardins, L Villeneuve, J Cote, J Bounameaux, H Cirafici, P Demers, C van der Heul, C Kruip, M
Citation: Hr. Buller et al., Treatment of proximal deep vein thrombosis with a novel synthetic compound(SR90107A/ORG31540) with pure anti-factor Xa activity - A phase II evaluation, CIRCULATION, 102(22), 2000, pp. 2726-2731
Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as anantithrombotic agent a pilot study in the setting of coronary angioplasty
Authors: Vuillemenot, A Schiele, F Meneveau, N Claudel, S Donat, F Fontecave, S Cariou, R Samama, MM Bassand, JP
Citation: A. Vuillemenot et al., Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as anantithrombotic agent a pilot study in the setting of coronary angioplasty, THROMB HAEM, 81(2), 1999, pp. 214-220
Single-dose pharmacodynamics of clopidogrel
Authors: Thebault, JJ Kieffer, G Cariou, R
Citation: Jj. Thebault et al., Single-dose pharmacodynamics of clopidogrel, SEM THROMB, 25, 1999, pp. 3-8
Repeated-dose pharmacodynamics of clopidogrel in healthy subjects
Authors: Thebault, JJ Kieffer, G Lowe, GDO Nimmo, WS Cariou, R
Citation: Jj. Thebault et al., Repeated-dose pharmacodynamics of clopidogrel in healthy subjects, SEM THROMB, 25, 1999, pp. 9-14
Clopidogrel loading dose regimens: Kinetic profile of pharmacodynamic response in healthy subjects
Authors: Savcic, M Hauert, J Bachmann, F Wyld, PJ Geudelin, B Cariou, R
Citation: M. Savcic et al., Clopidogrel loading dose regimens: Kinetic profile of pharmacodynamic response in healthy subjects, SEM THROMB, 25, 1999, pp. 15-19
Long-term activity of clopidogrel: A three-month appraisal in healthy volunteers
Authors: Caplain, H Cariou, R
Citation: H. Caplain et R. Cariou, Long-term activity of clopidogrel: A three-month appraisal in healthy volunteers, SEM THROMB, 25, 1999, pp. 21-23
Prolonged heparin administration during clopidogrel treatment in healthy subjects
Authors: Caplain, H D'Honneur, G Cariou, R
Citation: H. Caplain et al., Prolonged heparin administration during clopidogrel treatment in healthy subjects, SEM THROMB, 25, 1999, pp. 61-64
Clopidogrel-rt-PA-heparin combination in the treatment of acute myocardialinfarction
Authors: Bassand, JP Cariou, R Grollier, G Kragten, J Wolf, JE Heyndrickx, GR
Citation: Jp. Bassand et al., Clopidogrel-rt-PA-heparin combination in the treatment of acute myocardialinfarction, SEM THROMB, 25, 1999, pp. 69-75
Risultati: 1-8 |